(Q45858720)

17 December 2017

title

Why commercialization of gene therapy stalled; examining the life cycles of gene therapy technologies (English)

1 reference

17 December 2017

0 references

1 reference

F D Ledley

1

1 reference

17 December 2017

L M McNamee

series ordinal

2

1 reference

17 December 2017

V Uzdil

series ordinal

3

1 reference

17 December 2017

I W Morgan

series ordinal

4

1 reference

17 December 2017

publication date

5 December 2013

1 reference

17 December 2017

published in

Gene Therapy

1 reference

17 December 2017

volume

21

1 reference

17 December 2017

issue

2

1 reference

17 December 2017

page(s)

188-194

1 reference

17 December 2017

https://scigraph.springernature.com/pub.10.1038/gt.2013.72

exact match

0 references

cites work

Gene therapy for human genetic disease?

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

21 January 2018

History of gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Progress and prospects: gene therapy clinical trials (part 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Gene therapy clinical trials worldwide to 2007--an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Adenovirus-associated virus vector-mediated gene transfer in hemophilia B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Effect of gene therapy on visual function in Leber's congenital amaurosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Safety and efficacy of gene transfer for Leber's congenital amaurosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Efficacy of gene therapy for X-linked severe combined immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Medicine. A comeback for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Critical issues in gene therapy commercialization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Chinese gene therapy. Splicing out the West?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Europe gives gene therapy the green light

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Gene therapy enters the pharma market: the short story of a long journey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Can the pharmaceutical industry reduce attrition rates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Efficacy of three vaccines in protecting Western Scrub-Jays (Aphelocoma californica) from experimental infection with West Nile virus: implications for vaccination of Island Scrub-Jays (Aphelocoma insularis).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Patterns of technological innovation in biotech

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Ten years of Orthoclone OKT3 (muromonab-CD3): a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Marketed therapeutic antibodies compendium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Emergence of a scientific and commercial research and development infrastructure for human gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Harmful potential of viral vectors fuels doubts over gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Advancing translational research through the NHLBI Gene Therapy Resource Program (GTRP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Gene therapy finds its niche

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Genzyme: 15 years of cell and gene therapy research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Gene therapy clinical trials worldwide to 2012 - an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Trends in biotech literature 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Trends in biotech literature 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Can literature analysis identify innovation drivers in drug discovery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

Making the biotech IPO work

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

7 January 2021

Effects of administration of two growth hormone-releasing hormone plasmids to gilts on sow and litter performance for the subsequent three gestations

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

7 January 2021

Monoclonal antibody successes in the clinic

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

7 January 2021

Organizational Scope and Investment: Evidence from the Drug Development Strategies and Performance of Biopharmaceutical Firms

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

7 January 2021

The growth of the cell death field: an analysis from the ISI-Science citation index

1 reference

https://api.crossref.org/works/10.1038%2FGT.2013.72

7 January 2021

Identifiers

DOI

10.1038/GT.2013.72

1 reference

17 December 2017

Dimensions Publication ID

0 references

1 reference

17 December 2017